Innovative MedTech Inc.

As of June 30, 2025, Innovative MedTech Inc. carries a market capitalization of 3.89M, placing it among publicly traded companies globally. Its enterprise value stands at 4.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, Innovative MedTech Inc. has 59.84M shares outstanding.

As of June 30, 2025, Innovative MedTech Inc. trades at a trailing price-to-earnings ratio of 2.19. The price-to-sales ratio is 6.49, and the price-to-book ratio stands at -3.69.

These figures are as of June 30, 2025. The EV/Sales ratio of 10.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.53M versus a market cap of 3.89M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Innovative MedTech Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -61.65, indicating conservative leverage, while an interest coverage ratio of -15.68 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) stands at 281.26, measuring how efficiently the asset base is converted into earnings. The company generates approximately 18,830.07 in revenue per employee across its workforce of 22.75, a quick read on workforce productivity versus industry peers.

As of the close on October 15, 2026, Innovative MedTech Inc.'s stock has declined approximately 98.85% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.29.

Over the twelve months ended June 30, 2025, Innovative MedTech Inc. generated 428,384.00 in revenue and converted that into 1.27M in net income, yielding earnings per share of -0.05. EBITDA reached -2.64M, while operating income came in at -2.66M.

As of June 30, 2025, Innovative MedTech Inc. holds 13,616.00 in cash and equivalents against 649,205.00 in total debt, resulting in a net debt position of 635,589.00. Total book value stands at -1.05M, with working capital of -1.28M providing operational flexibility.

Innovative MedTech Inc. produced 2.85M in operating cash flow over the twelve months ended June 30, 2025. After subtracting -11,555.00 in capital expenditures, free cash flow totaled 2.84M - equivalent to 0.07 per share.

These figures cover the twelve months ended June 30, 2025. The operating margin of -620.52 and net profit margin of 296.21 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield stands at 102.22, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -9.07, meaning Innovative MedTech Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Innovative MedTech Inc.'s most recent stock split took place on March 9, 2021.

As of June 30, 2025, Innovative MedTech Inc. has an Altman Z-Score of -279.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.